# Tennessee Regulators Find Over 650 Unlicensed Hemp Cannabinoid Sellers > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/unlicensed-hemp-cannabinoid-product-sellers-tennessee/ > **Published:** 2026-03-16T20:03:11-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:06:31-04:00 > **Clinical Summary:** Tennessee regulators identify over 650 unlicensed hemp cannabinoid product sellers, highlighting risks in unregulated markets for patients and clinicians. --- ✦ New CED Clinical Relevance #45 Clinical Context Background information relevant to the evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) landscape. PolicyHempSafetyIndustry Why This Matters Clinicians in Tennessee need to be aware that over 650 unlicensed sellers of hemp-derived cannabinoid products operate in their state, meaning patients may be purchasing unregulated products with unknown potency, purity, and contaminant levels. Without regulatory oversight of these products, patients lack assurance regarding ingredient accuracy and safety, increasing the risk of adverse effects or drug interactions that clinicians should screen for during patient consultations. This regulatory gap underscores the importance of clinicians asking patients directly about cannabinoid use and advising them to obtain products only from licensed, regulated sources when such sources are available. Clinical Summary Tennessee’s regulatory agency has identified over 650 unlicensed sellers of hemp-derived cannabinoid products (HDCPs) following implementation of new state oversight rules on January 1, highlighting substantial gaps in market compliance and [consumer protection](https://cedclinic.com/cannabis-mold-contamination-risks-safety-tips/) infrastructure. The discovery underscores a widespread problem of unregulated distribution channels where products lack mandatory testing, labeling verification, and quality assurance standards, creating significant risks for patients regarding cannabinoid potency, contaminant exposure, and accurate dosing information. This regulatory enforcement challenge reflects the broader national tension between rapid market expansion of hemp-derived products and state capacity to adequately oversee manufacturing and retail operations. Clinicians should be aware that many patients obtaining cannabinoid products may be purchasing from unregulated sources without verified product composition or safety data, complicating clinical assessment of actual cannabinoid exposure and adverse event attribution. For practitioners counseling patients on cannabis use, inquiring about product source and regulatory status is now an essential part of the clinical history, and patients should be educated to purchase only from licensed, regulated vendors that provide third-party testing documentation. Dr. Caplan’s Take “When we have over 650 unlicensed sellers operating in a single state, we’re essentially running a [public health](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) experiment without informed consent, and my patients are the subjects. Without standardized testing, dosing, and manufacturing oversight, I cannot reliably counsel patients on safety or efficacy, which fundamentally undermines the trust-based relationship that clinical medicine depends on.” Clinical Perspective Tennessee’s recent identification of over 650 unlicensed hemp-derived cannabinoid product sellers underscores a critical gap between regulatory intent and market reality that clinicians should understand when counseling patients. The proliferation of unregulated vendors—operating despite new state licensing requirements—means that patients purchasing these products may be exposed to unknown potencies, contaminants, and mislabeled ingredients, complicating informed decision-making in clinical practice. While hemp-derived cannabinoids are marketed as legal alternatives to scheduled cannabis products, the lack of enforcement creates a de facto unregulated marketplace where quality standards remain inconsistent, much like the broader cannabinoid landscape. Clinicians should remain aware that regulatory nascency in states like Tennessee does not guarantee product safety and that patient use of these items—often self-directed and promoted through unvetted channels—warrants explicit discussion about unknown risks and lack of standardized dosing. When patients 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Tennessee+Regulators+Find+More+Than+650+Unlicensed+Hemp+Cannabinoid+Product+Sellers+%40drcaplan&url=https%3A%2F%2Froundtable.io%2Fnews%2Famerican-hemp-monitor%2Fhemp%2Ftennessee-regulators-find-more-than-650-unlicensed-hemp-cannabinoid-product-sellers)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Froundtable.io%2Fnews%2Famerican-hemp-monitor%2Fhemp%2Ftennessee-regulators-find-more-than-650-unlicensed-hemp-cannabinoid-product-sellers)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Tennessee+Regulators+Find+More+Than+650+Unlicensed+Hemp+Cannabinoid+Product+Sellers+--+via+%40drcaplan.bsky.social+https%3A%2F%2Froundtable.io%2Fnews%2Famerican-hemp-monitor%2Fhemp%2Ftennessee-regulators-find-more-than-650-unlicensed-hemp-cannabinoid-product-sellers)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) Related Articles - [CED Digest: 230 Items — March 15, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-clinical-relevance-2026/) - [CED Digest: 436 Items — March 14, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) - [CED Digest: 405 Items — March 12, 2026](https://cedclinic.com/alabama-medical-cannabis-sales-2026-spring-launch/) 📰 Source: [https://roundtable.io/news/american-hemp-monitor/hemp/tennessee-regulators-find-more-than-650-unlicensed-hemp-cannabinoid-product-sellers](https://roundtable.io/news/american-hemp-monitor/hemp/tennessee-regulators-find-more-than-650-unlicensed-hemp-cannabinoid-product-sellers) Further Reading Evidence Watch[endocannabinoid system: CBD & Cortical Excitability Trial](https://cedclinic.com/cbd-intrinsic-anti-epileptic-properties-trial/) CED Clinic Blog[Cannabis-Infused Beverages as Alcohol Alternatives: New York at Five Years](https://cedclinic.com/cannabis-beverage-substitution-alcohol-new-york-five-years/) Cannabis Policy Wire[AM Policy Update: March 16, 2026](https://cedclinic.com/dea-scheduling-cannabis-rescheduling-march-16-2026/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Missouri attorney general warns of unsafe, mislabeled cannabis products](https://cedclinic.com/missouri-cannabis-product-safety-warning/) Explore concerns about mislabeled and unsafe cannabis products in Missouri, highlighting regulatory challenges similar to those in Tennessee. [Read More](https://cedclinic.com/missouri-cannabis-product-safety-warning/) [Ohio SB 56 to enforce removal of intoxicating THC products from unlicensed retailers](https://cedclinic.com/ohio-cannabis-enforcement-sb-56/) Learn about Ohio's legislative efforts to remove unlicensed THC products, reflecting broader regulatory trends affecting hemp markets. [Learn More](https://cedclinic.com/ohio-cannabis-enforcement-sb-56/) [Study Finds Licensed Cannabis Farms More Effective Than Bans in Deterring Unlicensed Cultivation](https://cedclinic.com/study-finds-licensed-cannabis-farms-more-effective-than-bans-in-deterring-unlicensed-cultivation/) Review research showing licensed cannabis farms reduce unlicensed cultivation, relevant to regulatory challenges in hemp product markets. [Explore Study](https://cedclinic.com/study-finds-licensed-cannabis-farms-more-effective-than-bans-in-deterring-unlicensed-cultivation/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).